サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1179737

皮膚がん治療市場：タイプ別、治療法別、流通チャネル別：世界の機会分析・産業予測、2021-2031年

Skin Cancer Treatment Market By Type, By Therapy, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 251 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
皮膚がん治療市場：タイプ別、治療法別、流通チャネル別：世界の機会分析・産業予測、2021-2031年
出版日: 2022年09月01日
発行: Allied Market Research
ページ情報: 英文 251 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

皮膚がんは、太陽からの有害な放射線によって引き起こされる一般的ながんの一種です。

日光にさらされた皮膚には、異常な色素沈着、膠原病、皮膚のしわ、日光角化症などの徴候が現れます。皮膚がんには、メラノーマと非メラノーマの2種類があります。非黒色腫には、基底細胞がんと扁平上皮がんの2種類があり、基底細胞がんは、扁平上皮がんと呼ばれ、扁平上皮がんは、非黒色腫と呼ばれます。非黒色腫性皮膚がんは、世界で2～300万人以上が罹患している、人々に発見された皮膚がんの中で最も一般的なタイプです。皮膚がんには、標的療法、化学療法、免疫療法などの薬物療法があります。

世界中の皮膚がんの非黒色腫と黒色腫の種類の有病率の増加、様々な皮膚がん治療の可用性、皮膚がん治療のための需要の増加は、正に皮膚がん治療市場の成長に影響を与える要因です。例えば、米国がん協会によると、2020年には、米国で毎年540万人が基底膜および扁平上皮がんと診断され、同じがんで死亡する人が2,000人いるとのことです。また、米国における基底膜および扁平上皮がんの推定患者数は330万人です。米国人に最も多く見られる皮膚がんの種類は基底細胞がんで、10人中8人が罹患しています。扁平上皮がんは、アメリカ人にはあまり見られません。また、皮膚がんの管理のための政府によって取られたイニシアチブと効果的な皮膚がん治療のための高度な治療法の製造および開発に関与する主要な選手は、皮膚がん治療市場を後押しする要因です。例えば、2020年にノバルティスAGは、ステージIIIのBRAF V600変異メラノーマ患者を治療するための製品Tafinlar+MekinistのCOMBI-AD臨床試験を発表し、がん再発のリスクが高いそれらの患者のために効率的で長期の効果を提供するために手術を提供するために、。また、病院薬局や薬剤、診断センター、病院などの利用可能性が市場の成長に影響を与えます。しかし、化学療法や放射線療法による皮膚がん治療の使用に伴う副作用が、市場の成長を抑制しています。製品承認数の増加や皮膚がん治療のための先進的な治療法の出現は、市場成長の機会となっています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析
  • 特許情勢

第4章 皮膚がん治療市場：タイプ別

  • 概要
    • 市場規模および予測
  • メラノーマ
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 非メラノーマ
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
    • 非黒色腫皮膚がん治療市場：タイプ別
      • 基底細胞がんの市場規模・予測：地域別
      • 扁平上皮がんの市場規模・予測：地域別
      • その他市場規模・予測：地域別

第5章 皮膚がん治療市場：治療法別

  • 概要
    • 市場規模・予測
  • 免疫療法
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 標的治療薬
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 化学療法
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第6章 皮膚がん治療市場：流通チャネル別

  • 概要
    • 市場規模および予測
  • 病院薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測： 地域別
    • 市場分析：国別
  • ドラッグストア、小売薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • オンラインプロバイダー
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第7章 皮膚がん治療市場：地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主要動向と機会
    • 北米市場規模・予測：タイプ別
      • 北米の非黒色腫皮膚がん治療市場：タイプ別
    • 北米市場規模・予測：治療法別
    • 北米市場規模・予測：流通チャネル別
    • 北米市場規模・予測：国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な動向と機会
    • 欧州の市場規模・予測：タイプ別
      • 欧州の非黒色腫皮膚がん治療市場：タイプ別
    • 欧州市場規模・予測：治療法別
    • 欧州市場規模・予測：流通チャネル別
    • 欧州市場規模・予測：国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他の欧州地域
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測：タイプ別
      • アジア太平洋地域の非黒色腫皮膚がん治療市場：タイプ別
    • アジア太平洋地域の市場規模・予測：治療法別
    • アジア太平洋地域の市場規模・予測：流通チャネル別
    • アジア太平洋地域の市場規模・予測：国別
      • 日本
      • 中国
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測：タイプ別
      • LAMEAの非黒色腫皮膚がん治療市場：タイプ別
    • LAMEAの市場規模・予測：治療法別
    • LAMEAの市場規模・予測：流通チャネル別
    • LAMEAの市場規模・予測：国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ共和国
      • LAMEAの残りの地域

第8章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第9章 企業プロファイル

  • Amgen Inc.
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Glaxosmithkline plc
  • LEO Pharma
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
図表

LIST OF TABLES

  • TABLE 1. GLOBAL SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 2. SKIN CANCER TREATMENT MARKET, FOR MELANOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. SKIN CANCER TREATMENT MARKET FOR MELANOMA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. SKIN CANCER TREATMENT MARKET, FOR NON-MELANOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. SKIN CANCER TREATMENT MARKET FOR NON-MELANOMA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. GLOBAL NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 7. SKIN CANCER TREATMENT MARKET, FOR BASAL CELL CARCINOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. SKIN CANCER TREATMENT MARKET, FOR SQUAMOUS CELL CARCINOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. SKIN CANCER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. GLOBAL SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 11. SKIN CANCER TREATMENT MARKET, FOR IMMUNOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. SKIN CANCER TREATMENT MARKET FOR IMMUNOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. SKIN CANCER TREATMENT MARKET, FOR TARGETED THERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. SKIN CANCER TREATMENT MARKET FOR TARGETED THERAPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. SKIN CANCER TREATMENT MARKET, FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. SKIN CANCER TREATMENT MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. GLOBAL SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 18. SKIN CANCER TREATMENT MARKET, FOR HOSPITALS PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. SKIN CANCER TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 20. SKIN CANCER TREATMENT MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 21. SKIN CANCER TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 22. SKIN CANCER TREATMENT MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. SKIN CANCER TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 24. SKIN CANCER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 26. NORTH AMERICA NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 30. U.S. SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 31. U.S. SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 32. U.S. SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 33. CANADA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 34. CANADA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 35. CANADA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 36. MEXICO SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 37. MEXICO SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 38. MEXICO SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 39. EUROPE SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 40. EUROPE NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 41. EUROPE SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 42. EUROPE SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 43. EUROPE SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 44. GERMANY SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 45. GERMANY SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 46. GERMANY SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 47. FRANCE SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 48. FRANCE SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 49. FRANCE SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 50. UK SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 51. UK SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 52. UK SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 53. ITALY SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 54. ITALY SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 55. ITALY SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 56. SPAIN SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 57. SPAIN SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 58. SPAIN SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 59. REST OF EUROPE SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 60. REST OF EUROPE SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 61. REST OF EUROPE SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 62. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 63. ASIA-PACIFIC NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 64. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 66. ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 67. JAPAN SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 68. JAPAN SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 69. JAPAN SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 70. CHINA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 71. CHINA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 72. CHINA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 73. INDIA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 74. INDIA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 75. INDIA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 76. AUSTRALIA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 77. AUSTRALIA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 78. AUSTRALIA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 79. SOUTH KOREA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 80. SOUTH KOREA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH KOREA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 82. REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 83. REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 84. REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 85. LAMEA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 86. LAMEA NON-MELANOMA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 87. LAMEA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 88. LAMEA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 89. LAMEA SKIN CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 90. BRAZIL SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 91. BRAZIL SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 92. BRAZIL SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 93. SAUDI ARABIA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 94. SAUDI ARABIA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 95. SAUDI ARABIA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 96. SOUTH AFRICA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 97. SOUTH AFRICA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 98. SOUTH AFRICA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 99. REST OF LAMEA SKIN CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 100. REST OF LAMEA SKIN CANCER TREATMENT MARKET, BY THERAPY, 2021-2031 ($MILLION)
  • TABLE 101. REST OF LAMEA SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 102.AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 103.AMGEN INC.: OPERATING SEGMENTS
  • TABLE 104.AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 105.AMGEN INC.: NET SALES,
  • TABLE 106.AMGEN INC.: KEY STRATERGIES
  • TABLE 107.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 108.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
  • TABLE 109.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 110.BRISTOL-MYERS SQUIBB: NET SALES,
  • TABLE 111.BRISTOL-MYERS SQUIBB: KEY STRATERGIES
  • TABLE 112.F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
  • TABLE 113.F. HOFFMANN-LA ROCHE: OPERATING SEGMENTS
  • TABLE 114.F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
  • TABLE 115.F. HOFFMANN-LA ROCHE: NET SALES,
  • TABLE 116.F. HOFFMANN-LA ROCHE: KEY STRATERGIES
  • TABLE 117.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 118.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 119.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 120.GLAXOSMITHKLINE PLC: NET SALES,
  • TABLE 121.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 122.LEO PHARMA: COMPANY SNAPSHOT
  • TABLE 123.LEO PHARMA: OPERATING SEGMENTS
  • TABLE 124.LEO PHARMA: PRODUCT PORTFOLIO
  • TABLE 125.LEO PHARMA: NET SALES,
  • TABLE 126.LEO PHARMA: KEY STRATERGIES
  • TABLE 127.MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 128.MERCK KGAA: OPERATING SEGMENTS
  • TABLE 129.MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 130.MERCK KGAA: NET SALES,
  • TABLE 131.MERCK KGAA: KEY STRATERGIES
  • TABLE 132.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 133.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 134.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 135.NOVARTIS AG: NET SALES,
  • TABLE 136.NOVARTIS AG: KEY STRATERGIES
  • TABLE 137.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 138.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 139.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 140.PFIZER INC.: NET SALES,
  • TABLE 141.PFIZER INC.: KEY STRATERGIES
  • TABLE 142.REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 143.REGENERON PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 144.REGENERON PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 145.REGENERON PHARMACEUTICALS, INC.: NET SALES,
  • TABLE 146.REGENERON PHARMACEUTICALS, INC.: KEY STRATERGIES
  • TABLE 147.SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 148.SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 149.SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 150.SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
  • TABLE 151.SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.SKIN CANCER TREATMENT MARKET SEGMENTATION
  • FIGURE 2.SKIN CANCER TREATMENT MARKET,2021-2031
  • FIGURE 3.SKIN CANCER TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.SKIN CANCER TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.PATENT ANALYSIS BY COMPANY
  • FIGURE 13.PATENT ANALYSIS BY COUNTRY
  • FIGURE 14.SKIN CANCER TREATMENT MARKET,BY TYPE,2021(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF MELANOMA SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF NON-MELANOMA SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 17.SKIN CANCER TREATMENT MARKET,BY THERAPY,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF IMMUNOTHERAPY SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF TARGETED THERAPY SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 21.SKIN CANCER TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITALS PHARMACIES SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS SKIN CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 25.SKIN CANCER TREATMENT MARKET BY REGION,2021
  • FIGURE 26.U.S. SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 27.CANADA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.MEXICO SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.GERMANY SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.FRANCE SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.UK SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.ITALY SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.SPAIN SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.REST OF EUROPE SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.JAPAN SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.CHINA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.INDIA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.AUSTRALIA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.SOUTH KOREA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.REST OF ASIA-PACIFIC SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.BRAZIL SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.SAUDI ARABIA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 43.SOUTH AFRICA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 44.REST OF LAMEA SKIN CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 49.COMPETITIVE DASHBOARD
  • FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 51.AMGEN INC..: NET SALES ,($MILLION)
  • FIGURE 52.BRISTOL-MYERS SQUIBB.: NET SALES ,($MILLION)
  • FIGURE 53.F. HOFFMANN-LA ROCHE.: NET SALES ,($MILLION)
  • FIGURE 54.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
  • FIGURE 55.LEO PHARMA.: NET SALES ,($MILLION)
  • FIGURE 56.MERCK KGAA.: NET SALES ,($MILLION)
  • FIGURE 57.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 58.PFIZER INC..: NET SALES ,($MILLION)
  • FIGURE 59.REGENERON PHARMACEUTICALS, INC..: NET SALES ,($MILLION)
  • FIGURE 60.SUN PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)
目次
Product Code: A17526

Skin cancer is common type of cancer caused due to sun's harmful radiation. The abnormal pigmentation, collagenosis, skin wrinkling, and solar keratosis on sun-exposed skin are the signs associated with skin cancer. There are two types of skin cancers including melanoma and non-melanoma. There are two types of non-melanoma cancers which includes basal cell carcinoma and squamous cell carcinoma. Non-melanocytic skin cancer is the most prevalent type of skin cancer detected in people which affects over 2-3 million people worldwide. There are several medicated treatments available for skin cancer which includes targeted therapy, chemotherapy, and immunotherapy.

Increase in prevalence of non-melanoma and melanoma type of skin cancer across the globe, availability of various skin cancer treatments, and increased demand for skin cancer treatment are the factors that positively influence the skin cancer treatment market growth. For instance, according to the American Cancer Society, in 2020, 5.4 million people were diagnosed with basal and squamous skin cancer in the U.S. each year and there are 2,000 people die with same cancer. As per the same source, estimated number of people suffering from basal and squamous skin cancer in U.S. is 3.3 million. The most common type of skin cancer frequently observed in American people is basal cell cancer with 8 out of 10 people.  Squamous cell cancer is less likely observed in American people. In addition, initiatives taken by governments for the management of skin cancer and key players involved in the manufacturing and development of the advanced therapies for the effective skin cancer treatment are the factor boost skin cancer treatment market. For instance, in 2020, Novartis AG announced COMBI-AD clinical trial for the products Tafinlar + Mekinist to treat stage III BRAF V600-mutated melanoma patients to provide surgery to provide efficient, long-term effect for those patients who have high risk of cancer recurrence. In addition, availability of hospital pharmacies and drugs, diagnostic centers and hospitals influence the market growth. However, side effects associated with use of chemotherapy and radiotherapy skin cancer treatment restrain the market growth. Rise in number of product approvals and emergence of advanced therapies for skin cancer treatment are opportunities for the market growth.

The global skin cancer treatment market is segmented on the basis of type, therapy, distribution channel, and region. By type, the market is classified into melanoma and non-melanoma. The non-melanoma segment is further segmented into basal cell carcinoma, squamous cell carcinoma, and others. By therapy, the market is classified into immunotherapy, targeted therapy, and chemotherapy. By distribution channel, it is classified into hospitals pharmacies, drug stores & retail pharmacies, and online providers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global skin cancer treatment market are Amgen Inc, Bristol Myers Squibb Company, F. Hoffman-La-Roche Ltd, GlaxoSmithKline Plc., LEO Pharm A/S, Merck KGAA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals and, Sun Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the skin cancer treatment market analysis from 2021 to 2031 to identify the prevailing skin cancer treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the skin cancer treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global skin cancer treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution Channel

  • Hospitals Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Type

  • Melanoma
  • Non-Melanoma
    • Type
    • Basal Cell Carcinoma
    • Squamous Cell Carcinoma
    • Others

By Therapy

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Amgen Inc.
    • Bristol-Myers Squibb
    • F. Hoffmann-La Roche
    • Glaxosmithkline plc
    • LEO Pharma
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Patent Landscape

CHAPTER 4: SKIN CANCER TREATMENT MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Melanoma
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Non-Melanoma
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
    • 4.3.4 Non-Melanoma Skin Cancer Treatment Market by Type
      • 4.3.4.1 Basal Cell Carcinoma Market size and forecast, by region
      • 4.3.4.2 Squamous Cell Carcinoma Market size and forecast, by region
      • 4.3.4.3 Others Market size and forecast, by region

CHAPTER 5: SKIN CANCER TREATMENT MARKET, BY THERAPY

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Immunotherapy
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Targeted Therapy
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Chemotherapy
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Drug Stores and Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online Providers
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: SKIN CANCER TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Type
      • 7.2.2.1 North America Non-Melanoma Skin Cancer Treatment Market by Type
    • 7.2.3 North America Market size and forecast, by Therapy
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Type
      • 7.2.5.1.2 Market size and forecast, by Therapy
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Type
      • 7.2.5.2.2 Market size and forecast, by Therapy
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Type
      • 7.2.5.3.2 Market size and forecast, by Therapy
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Type
      • 7.3.2.1 Europe Non-Melanoma Skin Cancer Treatment Market by Type
    • 7.3.3 Europe Market size and forecast, by Therapy
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Type
      • 7.3.5.1.2 Market size and forecast, by Therapy
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Type
      • 7.3.5.2.2 Market size and forecast, by Therapy
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Type
      • 7.3.5.3.2 Market size and forecast, by Therapy
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Type
      • 7.3.5.4.2 Market size and forecast, by Therapy
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Type
      • 7.3.5.5.2 Market size and forecast, by Therapy
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Type
      • 7.3.5.6.2 Market size and forecast, by Therapy
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Type
      • 7.4.2.1 Asia-Pacific Non-Melanoma Skin Cancer Treatment Market by Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Therapy
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Type
      • 7.4.5.1.2 Market size and forecast, by Therapy
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Type
      • 7.4.5.2.2 Market size and forecast, by Therapy
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Type
      • 7.4.5.3.2 Market size and forecast, by Therapy
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Market size and forecast, by Type
      • 7.4.5.4.2 Market size and forecast, by Therapy
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Type
      • 7.4.5.5.2 Market size and forecast, by Therapy
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Type
      • 7.4.5.6.2 Market size and forecast, by Therapy
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Type
      • 7.5.2.1 LAMEA Non-Melanoma Skin Cancer Treatment Market by Type
    • 7.5.3 LAMEA Market size and forecast, by Therapy
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Type
      • 7.5.5.1.2 Market size and forecast, by Therapy
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Type
      • 7.5.5.2.2 Market size and forecast, by Therapy
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Type
      • 7.5.5.3.2 Market size and forecast, by Therapy
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Type
      • 7.5.5.4.2 Market size and forecast, by Therapy
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Amgen Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Bristol-Myers Squibb
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 F. Hoffmann-La Roche
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Glaxosmithkline plc
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 LEO Pharma
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Merck KGaA
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Novartis AG
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Pfizer Inc.
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Regeneron Pharmaceuticals, Inc.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Sun Pharmaceutical Industries Ltd.
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments